How to Read Pregnancy Category and Lactation Labeling on Drugs

When you’re pregnant or breastfeeding, knowing whether a medication is safe isn’t as simple as looking for an A, B, C, D, or X on the label anymore. That old system is gone. Since June 30, 2015, the U.S. Food and Drug Administration (FDA) has required all prescription drugs to use a new, detailed format called the Pregnancy and Lactation Labeling Rule (PLLR). This change was made because the old letter categories confused doctors and patients alike. Many thought an "A" meant completely safe and an "X" meant deadly - but the truth is far more complicated. The new system doesn’t give you a grade. It gives you facts.

What Replaced the Old Pregnancy Letter Categories?

Before 2015, drugs were labeled with one of five letters:

• A - Adequate human studies showed no risk (only 2% of drugs)
• B - Animal studies showed no risk, but human data was limited (15% of drugs)
• C - Risk can’t be ruled out (70% of drugs)
• D - Evidence of human risk (10% of drugs)
• X - Contraindicated in pregnancy (less than 1% of drugs)

These letters were meant to summarize risk, but they didn’t explain why a drug was categorized that way. A "C" could mean minor risk in animals with no human data - or it could mean serious birth defects seen in a small number of cases. There was no way to tell. The FDA found that 68% of healthcare providers misinterpreted these categories as a safety ranking. That’s why they replaced them.

The Three New Sections You Need to Know

Under the PLLR, every drug label now has three mandatory subsections under Section 8: Pregnancy (8.1), Lactation (8.2), and Females and Males of Reproductive Potential (8.3). Each one follows the same structure:

1. Risk Summary - What we know about the drug’s effect on pregnancy or breastfeeding
2. Clinical Considerations - What you should do in real life - when to test, monitor, or adjust
3. Data - The science behind the summary: which studies, how many people, what limitations

Let’s break down what each one means.

Pregnancy (8.1): Risk Summary

This section starts by telling you the background risk of birth defects and miscarriage - even without any medication. About 3% of all pregnancies have a major birth defect. Up to 20% of known pregnancies end in miscarriage. That’s your baseline.

Then it tells you how the drug changes that risk. For example:

• "Exposure to this drug during the first trimester is associated with a 1.5-fold increased risk of neural tube defects compared to the background rate of 0.1%"
• "No increase in major malformations was observed in 850 exposed pregnancies"

Notice how it doesn’t say "safe" or "dangerous." It says what happened in studies. It also tells you if the risk is higher at certain times - like "risk is greatest between weeks 6 and 10 of gestation." That’s critical. A drug might be risky early on but harmless later.

Pregnancy (8.1): Clinical Considerations

This is where you find actionable advice. Examples:

• "Consider alternative therapies during the first trimester if possible."
• "Monitor fetal growth with ultrasound every 4 weeks after 20 weeks gestation."
• "Pregnancy exposure registry: [Name and contact info]"

Many drugs now list an active pregnancy registry. These are real-world data collections - not just lab studies. As of 2023, there are 47 such registries tracking outcomes for drugs like antidepressants, epilepsy medications, and biologics. If you take one of these drugs while pregnant, you may be asked to join. It’s not mandatory, but it helps future patients.

Pregnancy (8.1): Data

This section dives into the studies. You’ll see things like:

• "Prospective cohort study of 1,200 pregnant women, 95% confidence interval: 1.2-1.9"
• "Retrospective analysis of 320 cases, limited by recall bias"

You don’t need to be a statistician to read this. If a study only had 30 people, the data is weak. If it’s a registry with thousands of cases over 10 years, it’s stronger. Look for phrases like "no controlled studies" - that means we’re guessing based on accidental exposures.

Lactation (8.2): How the Drug Gets Into Breast Milk

This section is often overlooked, but it’s just as important. Breastfeeding mothers need to know: how much of the drug ends up in milk, and what effect it might have on the baby.

Look for numbers like:

• "Infant exposure is estimated at 4% of the maternal weight-adjusted dose"
• "Peak milk concentration occurs 1-2 hours after maternal dose"
• "No adverse effects reported in 150 breastfed infants exposed to this drug"

Here’s what those numbers mean: if a mom takes 500 mg of a drug, and the infant gets 4% of that dose, that’s 20 mg. Is that safe? It depends on the drug. Some drugs are harmless at low levels; others can affect a baby’s liver or brain. The label tells you if any side effects were seen - like drowsiness, poor feeding, or jaundice.

Some drugs have no data. That doesn’t mean they’re dangerous - it means no one has studied it. In those cases, the label will say: "No data available on excretion in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for this drug."

Females and Males of Reproductive Potential (8.3)

This section isn’t just for women. It’s for anyone who could become pregnant - or whose partner could become pregnant. It answers:

• "Should you take a pregnancy test before starting this drug?"
• "What contraception method is recommended?"
• "What’s the failure rate of that method?"
• "Is infertility a known side effect?"

For example, some acne medications or cancer drugs can cause birth defects. So the label says: "Use two reliable forms of contraception during treatment and for one month after. Confirm pregnancy status before each prescription fill." It even tells you how often to test - "every 30 days" - and what tests to use.

It’s not just about avoiding pregnancy. It’s about planning for it. If a drug affects fertility, the label will say so.

Why the New System Is Better - and Harder

The PLLR gives you real information, not a shortcut. A 2017 FDA study showed that only 31% of providers misinterpreted the new labels - down from 68% with the old letters. That’s progress. But it comes at a cost.

Drug labels are now 300-500 words longer. A busy doctor can’t read all of it in a 10-minute visit. A 2018 study found that 62% of obstetricians felt overwhelmed at first. Family doctors, who often prescribe to pregnant patients, reported feeling less confident after the change. One survey showed 57% of family physicians now rely on outside resources like MotherToBaby or TERIS to interpret the data.

That’s okay. You’re not expected to memorize this. The goal isn’t speed - it’s accuracy. If you’re unsure, ask for help. Pharmacists are trained to interpret these labels. Many hospitals now have perinatal pharmacists on staff.

What to Do If You’re Still Confused

You don’t have to figure this out alone. Here’s what works:

• Use MotherToBaby - A free service run by the California Teratogen Information Service. Call them or visit their website. They explain drug risks in plain language.
• Ask your pharmacist - They get training on PLLR labels. Most can explain the risk summary in under a minute.
• Check the FDA’s PLLR Navigator app - Search any drug and pull up the exact pregnancy and lactation section.
• Join a pregnancy registry - If your drug has one, sign up. Your data helps others.

Don’t rely on Google searches or social media. A Reddit post or TikTok video won’t tell you how much drug gets into breast milk or whether the risk is real or just a statistical blip.

What’s Next? The Future of Drug Labeling

The FDA is working on making PLLR labels even clearer. In 2023, they proposed adding simple icons - like a green check, yellow warning, or red stop sign - to go with the text. They’re also pushing for better data on racial diversity in pregnancy registries. Right now, only 15% of participants are Black or Hispanic, even though those groups make up 30% of U.S. pregnancies.

By 2025, the FDA plans to update every single pregnancy-related drug label. They’re also requiring new drugs to include lactation pharmacokinetic data - meaning exact measurements of how much drug enters milk, not just estimates.

The system isn’t perfect. But it’s the best we’ve ever had. The old letter system gave false comfort. The new system gives real knowledge - even if it takes a little more time to understand.